CTI BIOPHARMA CORP
CTIC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CTIC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2023.
Tracking 2 pipeline candidates · 1 clinical trial for CTI BIOPHARMA CORP.
Similar companies
Run CTI BIOPHARMA CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CTI BIOPHARMA CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
6.3 months
OCF -$31M · Net income -$13M
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is CTI BIOPHARMA CORP's lead drug candidate?
CTI BIOPHARMA CORP's most advanced tracked candidate is pacritinib (Phase 3) for Severe COVID-19.
Who is the CEO of CTI BIOPHARMA CORP?
Adam R. Craig M.D. is the chief executive officer of CTI BIOPHARMA CORP (CTIC).
What therapeutic areas does CTI BIOPHARMA CORP focus on?
CTI BIOPHARMA CORP develops therapies across Oncology, Infectious Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.